Aadi Bioscience Inc., a clinical stage biopharmaceutical company focused on treating diseases related to mTOR activation, said it has raised $23 million in a series A funding round.
Pacific Palisades, California-based Aadi said it plans to use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.
The financing round was led by Hermed Capital with participation from Celgene Corp. (Nasdaq: CELG), Vivo Capital, Decheng Capital, the Helsinn Investment Fund…
Aadi Bioscience Inc., a clinical stage biopharmaceutical company focused on treating diseases related to mTOR activation, said it has raised $23 million in a series A funding round.
Pacific Palisades, California-based Aadi said it plans to use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.
The financing round was led by Hermed Capital with participation from Celgene Corp. (Nasdaq: CELG), Vivo Capital, Decheng Capital, the Helsinn Investment Fund…